You are here

Cellectis

SITC: Cellectis' off-the-shelf CAR-T for pancreatic cancer and mesothelioma shows activity in mice

SITC: Cellectis' off-the-shelf CAR-T for pancreatic cancer and mesothelioma shows activity in mice

Fierce Biotech

pancreatic cancer

Flag link:

Sanofi, Cellectis team up to pair Lemtrada with allogeneic CAR-Ts; Bristol Myers joins Evotec's drive to advance UK science

Sanofi, Cellectis team up to pair Lemtrada with allogeneic CAR-Ts; Bristol Myers joins Evotec's drive to advance UK science

Endpoints

allogeneic cells

Flag link:

FDA gives Cellectis all clear after patient death halted off-the-shelf CAR-T trial

FDA gives Cellectis all clear after patient death halted off-the-shelf CAR-T trial

Endpoints

clinical trials

Multiple Myeloma

Flag link:

Death in Cellectis off-the-shelf CAR-T trial triggers FDA hold

Death in Cellectis off-the-shelf CAR-T trial triggers FDA hold

Fierce Biotech

Multiple Myeloma

Flag link:

Cellectis boosts its coffers in revised off-the-shelf CAR-T deal with Servier

Cellectis boosts its coffers in revised off-the-shelf CAR-T deal with Servier

Endpoints

Flag link:

Cellectis gene editing patent upheld in Europe

Cellectis gene editing patent upheld in Europe

Seeking Alpha

Flag link:

FDA lifts hold on Cellectis’ CAR-T trial, adds go-slow caveat

FDA lifts hold on Cellectis’ CAR-T trial, adds go-slow caveat

Fierce Biotech

clinical trials

Flag link:

New Guidelines Address CAR-T Immunotherapy Toxicities to Prevent Patient Deaths

New Guidelines Address CAR-T Immunotherapy Toxicities to Prevent Patient Deaths

Xtalks

Juno Therapeutics

Flag link:

Patient Death Triggers FDA Hold For Cellectis’s “Off the Shelf” CAR-T

Patient Death Triggers FDA Hold For Cellectis’s “Off the Shelf” CAR-T

Xconomy

clinical trials

Flag link:

Medivir out-licenses hep C drug to China’s Ascletis; Cellectis launches pioneering UCART123 US study

Medivir out-licenses hep C drug to China’s Ascletis; Cellectis launches pioneering UCART123 US study

Endpoints

Flag link:

Servier, Pfizer get FDA OK to start US testing of an off-the-shelf CAR-T from Cellectis

Servier, Pfizer get FDA OK to start US testing of an off-the-shelf CAR-T from Cellectis

Endpoints

acute lymphocytic leukemia

Flag link:

Pfizer snags U.S. rights to Cellectis' white-hot CAR-T therapy

Pfizer snags U.S. rights to Cellectis' white-hot CAR-T therapy

Fierce Biotech

immuno-oncology

Flag link:

Cellectis makes history as CAR-T therapy clears terminal leukemia in baby girl

Cellectis makes history as CAR-T therapy clears terminal leukemia in baby girl

BioPharma Dive

Flag link:

Buzz: Cellectis could be in line for a $1.6B Pfizer buyout

Buzz: Cellectis could be in line for a $1.6B Pfizer buyout

Fierce Biotech

Flag link:

Cellectis upscales IPO toward $200M as CAR-T fever continues

Cellectis upscales IPO toward $200M as CAR-T fever continues

Fierce Biotech

Flag link:

Safety concerns cloud early promise of powerful new cancer drugs

Safety concerns cloud early promise of powerful new cancer drugs

Yahoo/Reuters

Juno Therapeutics

Flag link:

Cellectis Is Late To The CAR-T Cell Race, But Could Finish First

Cellectis Is Late To The CAR-T Cell Race, But Could Finish First

Seeking Alpha

Flag link:

Pfizer: Struggling Through A Tough Time

Pfizer: Struggling Through A Tough Time

Seeking Alpha

Flag link:

Pfizer's Plan B In Immuno-Oncology: Collaboration With Smaller Companies

Pfizer's Plan B In Immuno-Oncology: Collaboration With Smaller Companies

Seeking Alpha

cancer immunotherapy

Flag link:

Cellectis Sees Independent Future After Pfizer Deal

Cellectis Sees Independent Future After Pfizer Deal

TheStreet.com

chimeric antigen receptor T-cell immunotherapies

Flag link:

Pages